The association of PDKs expression with poor prognosis and resistance to anti-cancer therapies is widely documented, and PDKs inhibition (which results in PDH activation) constitutes a potential therapeutic possibility in several cancer types, including PCa (28–34). This evidence concerns the gene PDP1 and posterior cortical atrophy.